« back to directory
Company Profile
Recce Pharmaceuticals Ltd
- www.recce.com.au
- https://twitter.com/ReccePharma
- https://www.linkedin.com/company/reccepharmaceuticals/
- Level 25, 88 Phillip Street, Aurora Place, Sydney, NSW, 2000, Australia
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals (ASX: RCE, FSE: R9Q) is pioneering New Classes of Synthetic Anti-Infectives designed to address the urgent global health threat posed by antibiotic resistant superbugs and emerging viral pathogens. Studies of RECCE® 327 (R327) have indicated a world’s first multi-layered mechanism of action that targets both bacterial cell membrane viability and intracellular energy production. R327 has also been awarded Qualified Infectious Disease Product designation by the FDA. Further to this designation, R327 has been included on the Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the only synthetic polymer and sepsis drug candidate in development. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.
Connect with Recce Pharmaceuticals: LinkedIn | Twitter (AU) | Twitter (EU) | YouTube